Charactistics of all patients in the two treatment groups at the time of entry to the study
| Placebo (n=139) | Lexipafant (n=151) | |
|---|---|---|
| Age (y) (median (range)) | 63 (31–79) | 63 (18–79) |
| Sex (M/F) | 83/56 | 83/68 |
| APACHE II score (median (range)) | 11 (4–29) | 10 (5–24) |
| Aetiology | ||
| Gall stones2-150 | 66 (47%) | 73 (48%) |
| Alcohol2-150 | 18 (13%) | 20 (13%) |
| Other | 3 (2%) | 4 (3%) |
| Unknown | 54 (40%) | 55 (37%) |
| No with organ failure | 59 (43%) | 67 (44%) |
| Respiratory | 53 (38%) | 58 (39%) |
| Cardiovascular | 2 (1%) | 0 |
| Renal | 11 (8%) | 10 (7%) |
| CNS | 2 (1%) | 0 |
| Coagulation | 3 (2%) | 5 (3%) |
| Inflammatory markers (median (IQR)) | ||
| IL-8 (pg/ml) | 31 (0–69) | 37 (0–80) |
| E-selectin (ng/ml) | 67 (51–100) | 70 (52–100) |
| IL-6 (pg/ml) | 195 (54–297) | 124 (46–243) |
| CRP (mg/l) | 83 (43–142) | 80 (34–144) |
| PMN elastase | 173 (105–295) | 185 (103–295) |
| Symptom duration before first dose | ||
| <24 hours | 35 (25%) | 34 (23%) |
| 24–48 hours | 63 (45%) | 73 (48%) |
| >48 hours | 41 (30%) | 44 (29%) |
IQR, interquartile range.
↵2-150 Two placebo and one lexipafant patient had both gall stones and alcohol.